John H. Abeles

Bryologyx, Inc. operates as a biopharmaceutical company focused on treating cancer immunotherapies. The company was founded by Thomas M. Loarie, John H. Abeles, Paul A. Wender and Sam Kongsamut and is headquartered in Danville, CA.

Bryologyx, Inc. operates as a biopharmaceutical company focused on treating cancer immunotherapies. The company was founded by Thomas M. Loarie, John H. Abeles, Paul A. Wender and Sam Kongsamut and is headquartered in Danville, CA.

Medisync Midwest LLC provides consultation services. It offers practice management partnership, clinical research, volume to value planning, diagnostic assessments, and HCC program. The company is headquartered in Cincinnati, OH.

I-Flow Corp. designs, develops and manufactures ambulatory drug delivery systems. Its products include portable infusion pumps, catheters and pain kits. The company was founded in 1985 and is headquartered in Lake Forest, CA.

OHK Medical Devices, Inc. develops and manufactures self-contained, sterile, exsanguinating tourniquet products. Its products include hand and wrist, foot and ankle, upper extremity, lower extremity and pediatrics. The company was founded by Noam Gavriely in 1999 and is headquartered in Grandville, MI.

OHK Medical Devices, Inc. develops and manufactures self-contained, sterile, exsanguinating tourniquet products. Its products include hand and wrist, foot and ankle, upper extremity, lower extremity and pediatrics. The company was founded by Noam Gavriely in 1999 and is headquartered in Grandville, MI.

Pattern Pharma, Inc. engages in the pharmaceutical industry. Its product named P2PAR addresses the immune failure which underlies infectious diseases and cancers. The company is headquartered in Toronto, Canada.

I-Flow Corp. designs, develops and manufactures ambulatory drug delivery systems. Its products include portable infusion pumps, catheters and pain kits. The company was founded in 1985 and is headquartered in Lake Forest, CA.

Oncolyze, Inc. is a private company developing a novel technology for cancer treatment. The company is based in New York, NY and was founded by Steven J. Evans and John H. Abeles. The company's lead drug candidate targets the cancer cell membrane and selectively kills cancer cells and cancer stem cells while sparing normal cells, potentially providing a highly effective treatment with little to no side effects. The initial therapeutic target is acute myeloid leukemia (AML), a cancer with a low five-year survival rate. Oncolyze's drug has been shown to destroy leukemic cancer stem cells, disrupting current medical treatment. Steven J. Evans has been the CEO since incorporation.

Pattern Pharma, Inc. engages in the pharmaceutical industry. Its product named P2PAR addresses the immune failure which underlies infectious diseases and cancers. The company is headquartered in Toronto, Canada.

Pattern Pharma, Inc. engages in the pharmaceutical industry. Its product named P2PAR addresses the immune failure which underlies infectious diseases and cancers. The company is headquartered in Toronto, Canada.

OHK Medical Devices, Inc. develops and manufactures self-contained, sterile, exsanguinating tourniquet products. Its products include hand and wrist, foot and ankle, upper extremity, lower extremity and pediatrics. The company was founded by Noam Gavriely in 1999 and is headquartered in Grandville, MI.

OHK Medical Devices, Inc. develops and manufactures self-contained, sterile, exsanguinating tourniquet products. Its products include hand and wrist, foot and ankle, upper extremity, lower extremity and pediatrics. The company was founded by Noam Gavriely in 1999 and is headquartered in Grandville, MI.

Oncolyze, Inc. is a private company developing a novel technology for cancer treatment. The company is based in New York, NY and was founded by Steven J. Evans and John H. Abeles. The company's lead drug candidate targets the cancer cell membrane and selectively kills cancer cells and cancer stem cells while sparing normal cells, potentially providing a highly effective treatment with little to no side effects. The initial therapeutic target is acute myeloid leukemia (AML), a cancer with a low five-year survival rate. Oncolyze's drug has been shown to destroy leukemic cancer stem cells, disrupting current medical treatment. Steven J. Evans has been the CEO since incorporation.

Bryologyx, Inc. operates as a biopharmaceutical company focused on treating cancer immunotherapies. The company was founded by Thomas M. Loarie, John H. Abeles, Paul A. Wender and Sam Kongsamut and is headquartered in Danville, CA.

Pattern Pharma, Inc. engages in the pharmaceutical industry. Its product named P2PAR addresses the immune failure which underlies infectious diseases and cancers. The company is headquartered in Toronto, Canada.

Bryologyx, Inc. operates as a biopharmaceutical company focused on treating cancer immunotherapies. The company was founded by Thomas M. Loarie, John H. Abeles, Paul A. Wender and Sam Kongsamut and is headquartered in Danville, CA.

Bryologyx, Inc. operates as a biopharmaceutical company focused on treating cancer immunotherapies. The company was founded by Thomas M. Loarie, John H. Abeles, Paul A. Wender and Sam Kongsamut and is headquartered in Danville, CA.

Bryologyx, Inc. operates as a biopharmaceutical company focused on treating cancer immunotherapies. The company was founded by Thomas M. Loarie, John H. Abeles, Paul A. Wender and Sam Kongsamut and is headquartered in Danville, CA.

OHK Medical Devices, Inc. develops and manufactures self-contained, sterile, exsanguinating tourniquet products. Its products include hand and wrist, foot and ankle, upper extremity, lower extremity and pediatrics. The company was founded by Noam Gavriely in 1999 and is headquartered in Grandville, MI.

OHK Medical Devices, Inc. develops and manufactures self-contained, sterile, exsanguinating tourniquet products. Its products include hand and wrist, foot and ankle, upper extremity, lower extremity and pediatrics. The company was founded by Noam Gavriely in 1999 and is headquartered in Grandville, MI.

International Opera Alliance is an entertainment company focused on musical and arts activities. The company is headquartered in Fairfax, VA.

Hadean Ventures AS (Hadean Ventures) is a venture capital firm that manages alternative investment funds. The firm was founded by Ingrid Helene Teigland Akay in 2014 and is headquartered in Oslo, Norway.

Alison Raffaele Cosmetics, Inc. manufactures cosmetics and facial makeup products. Its products include powder, lipstick, lip gloss and blush, tools, and brushes. The firm was founded by Alison Raffaele Tatem in 2000 and is headquartered in Cliffside Park, NJ.

OHK Medical Devices, Inc. develops and manufactures self-contained, sterile, exsanguinating tourniquet products. Its products include hand and wrist, foot and ankle, upper extremity, lower extremity and pediatrics. The company was founded by Noam Gavriely in 1999 and is headquartered in Grandville, MI.

Oncolyze, Inc. is a private company developing a novel technology for cancer treatment. The company is based in New York, NY and was founded by Steven J. Evans and John H. Abeles. The company's lead drug candidate targets the cancer cell membrane and selectively kills cancer cells and cancer stem cells while sparing normal cells, potentially providing a highly effective treatment with little to no side effects. The initial therapeutic target is acute myeloid leukemia (AML), a cancer with a low five-year survival rate. Oncolyze's drug has been shown to destroy leukemic cancer stem cells, disrupting current medical treatment. Steven J. Evans has been the CEO since incorporation.

Oncolyze, Inc. is a private company developing a novel technology for cancer treatment. The company is based in New York, NY and was founded by Steven J. Evans and John H. Abeles. The company's lead drug candidate targets the cancer cell membrane and selectively kills cancer cells and cancer stem cells while sparing normal cells, potentially providing a highly effective treatment with little to no side effects. The initial therapeutic target is acute myeloid leukemia (AML), a cancer with a low five-year survival rate. Oncolyze's drug has been shown to destroy leukemic cancer stem cells, disrupting current medical treatment. Steven J. Evans has been the CEO since incorporation.

Pattern Pharma, Inc. engages in the pharmaceutical industry. Its product named P2PAR addresses the immune failure which underlies infectious diseases and cancers. The company is headquartered in Toronto, Canada.